Hepatic Artery Embolization / Chemoembolization

Hepatic artery embolization is a family of catheter-directed therapies that exploit the dual blood supply of the liver: hepatocellular carcinoma (HCC) and most hypervascular liver tumors derive ≥90% of their blood supply from the hepatic artery, while normal hepatocytes are supplied primarily by the portal vein. Selective embolization of the tumor's arterial supply produces ischemic necrosis with relative sparing of the surrounding liver. The four major variants — bland transarterial embolization (TAE), conventional transarterial chemoembolization with lipiodol (cTACE), drug-eluting bead chemoembolization (DEB-TACE), and transarterial radioembolization with Yttrium-90 microspheres (TARE) — differ in mechanism and indication, but share this anatomic principle.

The dominant indication is unresectable, non-transplant-eligible HCC at Barcelona Clinic Liver Cancer (BCLC) stage B (intermediate-stage: multinodular, no vascular invasion, no extrahepatic spread, preserved liver function). AASLD, EASL, and APASL guidelines all recommend TACE as first-line therapy for BCLC B HCC. TACE is also used as a bridge to liver transplant (keeping HCC within Milan criteria during waitlist), as downstaging therapy (bringing tumors outside Milan back within criteria), or as palliation.

Additional indications include hypervascular liver metastases (most commonly neuroendocrine tumor metastases — where TAE/TACE is used both for tumor control and for hormonal symptom palliation in functional tumors), arteriovenous malformations, and post-traumatic or post-procedural hepatic artery bleeding. Yttrium-90 TARE has expanded indications to include selected HCC patients with segmental or lobar portal vein thrombosis, where the small-particle radioactive microspheres (≤60 μm) cause tumor kill by radiation rather than by arterial occlusion.

Workup includes triphasic CT or MRI to characterize the tumor, define arterial anatomy (especially replaced or accessory hepatic arteries), and assess portal vein patency. Liver function is evaluated by Child-Pugh and MELD scores, with attention to bilirubin, INR, albumin, ascites, and encephalopathy. Performance status (ECOG), tumor markers (AFP for HCC, chromogranin A for neuroendocrine), and viral hepatitis serologies complete the workup. For Y-90 TARE, an additional pre-treatment mapping angiogram with macroaggregated albumin (Tc-99m MAA) scan is performed to calculate lung shunt fraction (must be <10–20% depending on protocol) and to coil any extrahepatic branches that could cause non-target radiation injury.

Absolute contraindications to TACE include Child-Pugh C cirrhosis (decompensated liver disease cannot tolerate further ischemic insult), ECOG performance status >2, contrast or chemotherapy contraindication (severe renal failure, severe cytopenia), and no expected survival or quality-of-life benefit. Relative contraindications include bilirubin >3 mg/dL, main portal vein thrombosis (historically absolute, now relative in selected patients with adequate collateral hepatopetal flow and selective/segmental technique), tumor burden >50% of liver volume, decompensated cirrhosis with ascites or variceal bleeding, and hypovascular tumors (which do not concentrate the chemotherapy/embolic agent).

Biliary-enteric anastomosis (e.g., prior Whipple, Roux-en-Y hepaticojejunostomy) or incompetent sphincter of Oddi from prior sphincterotomy or stent is the strongest known risk factor for post-embolization liver abscess — abscess rates approach 20–30% in this subgroup without prophylaxis. Aggressive antibiotic prophylaxis with bowel preparation (neomycin/erythromycin pre-procedure, IV levofloxacin/metronidazole peri-procedure and oral continuation for 2 weeks) has been shown to substantially reduce this risk.

Arterial access is by femoral or radial puncture, with diagnostic angiography from the celiac axis and superior mesenteric artery to map hepatic arterial anatomy (replaced right hepatic from SMA in approximately 15%, replaced left hepatic from left gastric in approximately 10%, both relevant for catheter routing). A microcatheter is advanced as selectively as possible — segmental or subsegmental positioning where feasible — to minimize non-target liver injury. Branches supplying the gallbladder (cystic artery), stomach (right gastric, accessory left gastric), or duodenum that could cause off-target embolization are coiled or avoided.

Conventional TACE (cTACE) involves slow injection of a chemotherapy-lipiodol emulsion (most commonly doxorubicin, sometimes mitomycin or cisplatin) followed by an embolic agent (gelfoam, polyvinyl alcohol particles) until near-stasis is achieved in the tumor feeding vessel. Lipiodol is selectively retained in HCC for weeks to months (cleared from normal liver within ~4 weeks) and serves as both a drug carrier and a tumor-seeking imaging marker.

Drug-eluting bead TACE (DEB-TACE) uses pre-loaded calibrated microspheres (typically 100–300 μm or 70–150 μm) that simultaneously embolize and slowly elute doxorubicin over hours to days. Compared with cTACE, DEB-TACE delivers higher intratumoral drug concentrations with lower systemic exposure but has not consistently shown a survival advantage. Bland TAE (embolization without chemotherapy) is preferred for some indications, particularly neuroendocrine metastases and post-traumatic bleeding.

Y-90 TARE involves a separate session, typically 1–2 weeks after the mapping angiogram, in which calibrated radioactive microspheres (resin Y-90 or glass Y-90) are delivered selectively to the tumor-bearing segment(s). Because the particles are small (≤60 μm), they do not significantly alter hepatic arterial hemodynamics, allowing treatment in patients with portal vein thrombosis.

Most patients are admitted overnight after TACE or TARE. Standard care includes IV hydration, pain control (often requiring opioid PCA in the first 24 hours), antiemetics, and prophylactic antibiotics for patients with biliary risk factors. Liver function tests and complete blood count are checked the morning after the procedure.

Post-embolization syndrome — fever, right upper quadrant pain, nausea, vomiting, anorexia, malaise, and transient LFT elevation — occurs in 40–80% of patients after TACE. It is expected, not a complication per se, and reflects tumor necrosis and inflammatory response. Symptoms typically peak at 48–72 hours and resolve over 5–10 days with supportive care. Persistent or worsening fever beyond 7–10 days raises concern for liver abscess.

Imaging follow-up is by triphasic CT or MRI at 4–8 weeks, with response assessed by mRECIST or EASL criteria (which evaluate residual arterial enhancement of viable tumor rather than overall tumor size). Repeat TACE 'on-demand' for residual or recurrent enhancement is standard; fixed-interval re-treatment regimens have not demonstrated benefit and may worsen liver function.

Major complications occur in approximately 5–10% of TACE procedures. Liver failure is the most feared and can be precipitated by aggressive embolization in patients with marginal hepatic reserve — selective and subselective technique is the principal defense. Liver abscess (1–2% in average-risk patients, 20–30% in patients with biliary-enteric anastomosis without prophylaxis) presents 1–8 weeks after the procedure with persistent fever, leukocytosis, and RUQ pain. Management is percutaneous drainage and prolonged broad-spectrum antibiotics.

Biloma (intrahepatic bile collection from injury to peribiliary plexus) presents subacutely with pain or abnormal liver tests. Most respond to percutaneous drainage. Cholecystitis from non-target embolization of the cystic artery is usually managed conservatively but occasionally requires cholecystectomy. Less common but serious: tumor rupture (especially with subcapsular tumors), pulmonary embolization (especially with TARE if lung shunt fraction is high), variceal bleeding from worsened portal hypertension, gastric or duodenal ulceration from non-target embolization, and access-site complications (hematoma, pseudoaneurysm).

On the oral boards, examiners typically test: the dual blood supply of liver and the rationale for arterial-only embolization; the BCLC framework and which stage corresponds to TACE first-line; Child-Pugh and bilirubin cutoffs; portal vein thrombosis as a historical absolute and current relative contraindication; the strong association between biliary-enteric anastomosis and post-TACE abscess; and the recognition and management of post-embolization syndrome versus actual abscess.